Mohamad Navab Selected Research

Apolipoprotein A-I (Apolipoprotein A1)

1/2022	Oxidized phospholipids cause changes in jejunum mucus that induce dysbiosis and systemic inflammation.
1/2018	Treating the Intestine with Oral ApoA-I Mimetic Tg6F Reduces Tumor Burden in Mouse Models of Metastatic Lung Cancer.
2/2016	Carboxyl-Terminal Cleavage of Apolipoprotein A-I by Human Mast Cell Chymase Impairs Its Anti-Inflammatory Properties.
12/2015	Proinflammatory high-density lipoprotein results from oxidized lipid mediators in the pathogenesis of both idiopathic and associated types of pulmonary arterial hypertension.
8/2015	Efficacy of tomato concentrates in mouse models of dyslipidemia and cancer.
8/2014	Apolipoprotein A-I mimetic peptide 4F rescues pulmonary hypertension by inducing microRNA-193-3p.
11/2012	High-density lipoprotein and 4F peptide reduce systemic inflammation by modulating intestinal oxidized lipid metabolism: novel hypotheses and review of literature.
8/2012	Apolipoprotein A-I mimetic peptides inhibit expression and activity of hypoxia-inducible factor-1α in human ovarian cancer cell lines and a mouse ovarian cancer model.
6/2012	HDL mimetics inhibit tumor development in both induced and spontaneous mouse models of colon cancer.
3/2012	D-4F, an apoA-I mimetic peptide, inhibits proliferation and tumorigenicity of epithelial ovarian cancer cells by upregulating the antioxidant enzyme MnSOD.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mohamad Navab Research Topics

Disease

68	Atherosclerosis 01/2020 - 01/2002
39	Inflammation (Inflammations) 01/2022 - 04/2002
12	Coronary Disease (Coronary Heart Disease) 11/2017 - 08/2002
8	Cardiovascular Diseases (Cardiovascular Disease) 06/2013 - 01/2005
7	Dyslipidemias (Dyslipidemia) 10/2018 - 04/2003
7	Neoplasms (Cancer) 01/2018 - 11/2010
4	Atherosclerotic Plaque (Atheroma) 12/2020 - 12/2004
4	Chronic Kidney Failure (Chronic Renal Failure) 06/2011 - 08/2009
4	Human Influenza (Influenza) 11/2008 - 08/2002
4	Infections 08/2008 - 08/2002
3	Ovarian Neoplasms (Ovarian Cancer) 08/2012 - 11/2010
3	Acute-Phase Reaction 04/2011 - 08/2006
3	Cognitive Dysfunction 11/2008 - 10/2006
3	Coronary Artery Disease (Coronary Atherosclerosis) 09/2007 - 06/2002
2	Vascular Remodeling 01/2020 - 12/2015
2	Pulmonary Hypertension 01/2020 - 08/2014
2	Vascular Diseases (Vascular Disease) 12/2015 - 08/2014
2	Pulmonary Arterial Hypertension 12/2015 - 08/2014
2	Obesity 08/2015 - 04/2003
2	Hypoxia (Hypoxemia) 08/2014 - 08/2012
2	Body Weight (Weight, Body) 04/2013 - 01/2012
2	Proteinuria 11/2010 - 01/2010
2	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2010 - 08/2006
2	Insulin Resistance 01/2009 - 04/2003
2	Arthritis (Polyarthritis) 01/2009 - 05/2008
2	Heart Diseases (Heart Disease) 05/2007 - 03/2007
2	Cardiac Sudden Death (Sudden Cardiac Arrest) 10/2003 - 10/2003
2	Acute Coronary Syndrome 10/2003 - 10/2003
1	Dysbiosis 01/2022
1	Melanoma (Melanoma, Malignant) 12/2020
1	Fibrosis (Cirrhosis) 01/2020
1	Right Ventricular Dysfunction 01/2020
1	Left Ventricular Dysfunction 01/2020
1	Right Ventricular Hypertrophy 01/2020
1	Lung Neoplasms (Lung Cancer) 01/2018
1	Hypercholesterolemia 01/2017
1	Emphysema 01/2017
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2017
1	Reperfusion Injury 12/2013
1	Heart Failure 12/2013

Drug/Important Bio-Agent (IBA)

44	Peptides (Polypeptides)IBA 01/2022 - 01/2002
38	Apolipoprotein A-I (Apolipoprotein A1)IBA 01/2022 - 01/2002
29	LipidsIBA 01/2020 - 08/2002
24	HDL LipoproteinsIBA 01/2016 - 06/2002
20	ApolipoproteinsIBA 01/2016 - 06/2002
16	CholesterolIBA 08/2015 - 01/2002
14	oxidized low density lipoproteinIBA 01/2020 - 04/2002
13	LDL Receptors (LDL Receptor)IBA 01/2020 - 08/2002
13	HDL CholesterolIBA 04/2011 - 08/2002
12	AntioxidantsIBA 12/2013 - 04/2003
11	Phospholipids (Phosphatides)FDA LinkGeneric 01/2022 - 08/2002
11	Aryldialkylphosphatase (Paraoxonase)IBA 06/2011 - 06/2002
11	Lipoproteins (Lipoprotein)IBA 04/2011 - 04/2003
10	Proteins (Proteins, Gene)FDA Link 12/2020 - 01/2005
10	Apolipoproteins E (ApoE)IBA 01/2016 - 09/2004
8	lysophosphatidic acidIBA 04/2015 - 11/2010
6	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 11/2017 - 12/2003
5	Particulate MatterIBA 01/2017 - 03/2008
5	LDL Lipoproteins (beta Lipoproteins)IBA 06/2011 - 04/2003
4	Interleukin-6 (Interleukin 6)IBA 10/2018 - 08/2002
4	Triglycerides (Triacylglycerol)IBA 08/2015 - 01/2008
4	Biomarkers (Surrogate Marker)IBA 06/2012 - 08/2006
4	EnzymesIBA 03/2012 - 06/2002
4	Amino Acids FDA Link 01/2009 - 01/2002
3	oxidized- L- alpha- 1- palmitoyl- 2- arachidonoyl- sn- glycero- 3- phosphorylcholineIBA 11/2015 - 04/2002
3	apolipoprotein A-I mimetic peptide 4FIBA 08/2014 - 01/2009
3	Insulin (Novolin)FDA Link 08/2014 - 12/2010
3	Reactive Oxygen Species (Oxygen Radicals)IBA 02/2011 - 06/2004
2	Serum Amyloid A Protein (Serum Amyloid A)IBA 10/2018 - 04/2013
2	Lysophosphatidylcholines (Lysophosphatidylcholine)IBA 01/2017 - 04/2015
2	HemopexinIBA 01/2016 - 07/2009
2	Oxidants (Oxidizing Agents)IBA 12/2015 - 08/2010
2	Environmental Pollutants (Pollutants, Environmental)IBA 07/2013 - 03/2008
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 08/2012 - 04/2011
2	Fatty Acids (Saturated Fatty Acids)IBA 12/2010 - 08/2008
2	Arachidonic Acid (Vitamin F)IBA 12/2010 - 06/2004
2	ChemokinesIBA 01/2010 - 05/2008
2	Pravastatin (Pravachol)FDA LinkGeneric 01/2010 - 05/2008
2	Messenger RNA (mRNA)IBA 08/2009 - 01/2008
2	CytokinesIBA 05/2008 - 11/2004
2	LDL CholesterolIBA 09/2003 - 08/2002
1	Toll-Like Receptor 4IBA 10/2018
1	lipopolysaccharide-binding proteinIBA 10/2018
1	Cholestanol (Coprostanol)IBA 01/2017
1	SmokeIBA 01/2017
1	LysophospholipidsIBA 01/2017
1	Ezetimibe (Zetia)FDA Link 01/2017
1	Chymases (Chymase)IBA 02/2016
1	LipopolysaccharidesIBA 02/2016
1	Heme (Haem)IBA 01/2016
1	neuromedin UIBA 08/2015
1	PowdersIBA 08/2015
1	6F peptideIBA 08/2015
1	6- (3- (piperazin- 1- yl)propanoyl)benzo(d)oxazol- 2(3H)- oneIBA 04/2015
1	MonocrotalineIBA 08/2014
1	MicroRNAs (MicroRNA)IBA 08/2014
1	AcidsIBA 08/2014
1	LipoxygenasesIBA 08/2014

Therapy/Procedure

13	Therapeutics 12/2015 - 10/2003
3	Oral Administration 08/2006 - 01/2002